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AbstrACt
Introduction In multisite intervention trials, 
implementation success often varies widely across 
settings. Process evaluations are crucial to interpreting 
trial outcomes and understanding contextual factors and 
causal chains necessary for successful implementation. 
Lynch syndrome is a hereditary cancer predisposition 
conferring an increased risk of colorectal, endometrial and 
other cancer types. Despite systematic screening protocols 
to identify Lynch syndrome, the condition remains largely 
underdiagnosed. The Hide and Seek Project (‘HaSP’) is 
a cluster randomised controlled trial determining the 
effectiveness of two approaches to improving Lynch 
syndrome detection at eight Australian hospital networks. 
To enhance widespread implementation of optimal Lynch 
syndrome identification, there is a need to understand not 
only what works, but also why, in what contexts, and at 
what costs. Here we describe an in- depth investigation 
of factors influencing successful implementation of 
procedures evaluated in the HaSP trial.
Methods and analysis A mixed- methods, theory- driven 
process evaluation will be undertaken in parallel to the 
HaSP trial. Data will include: interviews of Implementation 
Leads and Lynch syndrome stakeholders, pre–post 
implementation questionnaires, audio analysis of meetings 
and focus groups, observation of multidisciplinary team 
meetings, fidelity checklists and project log analysis. 
Results will be triangulated and coded, drawing on the 
Theoretical Domains Framework, Consolidated Framework 
for Implementation Research and Proctor’s implementation 
outcomes.
Ethics and dissemination Use of a theory- based 
process evaluation will enhance interpretation and 
generalisability of HaSP trial findings, and contribute to the 
implementation research field by furthering understanding 
of the conditions necessary for implementation success. 
Ethical approval has been granted and results will be 
disseminated via publications in peer- reviewed journals 
and conference presentations. At trial completion, key 
findings will be fed back to sites to enable refinement 
of intervention strategies, both in the context of Lynch 
syndrome and for the possible generalisability of 
intervention components in other genetic and broader 
clinical specialties.
HasP trial registration number Australian 
New Zealand Clinical Trials Registry (Identifier: 
ACTRN12618001072202). Registered 27 June 2018. 
http://www. ANZCTR. org. au/ ACTRN12618001072202. aspx.
IntroduCtIon
The real- world implementation of clin-
ical practice change interventions within 
complex health systems is an ongoing chal-
lenge.1–3 Despite a growing body of research 
dedicated to the development of theories and 
frameworks to optimise the design and imple-
mentation of such interventions,4 5 success 
remains widely variable.6–9 While randomised 
controlled trials (RCTs) are important in 
establishing effectiveness,10 11 their tendency 
strengths and limitations of this study
 ► This in- depth process evaluation capitalises on the 
unique design of the Hide and Seek Project trial to 
advance understanding of the role and importance 
of theory in intervention design, mechanisms of im-
pact and factors affecting implementation success.
 ► The mixed- methods design allows triangulation of 
results to enhance confidence in study findings.
 ► Acknowledging intervention complexity, this process 
evaluation can only be used to generate inferences 
about causation.
 ► This process evaluation will enhance understanding 
about the generalisability of successful intervention 
components for implementation.
 ► Findings can be applied to other clinical problems 
within and beyond the setting of genetics and Lynch 
syndrome.
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to focus solely on clinical outcomes (eg, morbidity, 
mortality, symptomatology) and/or service system 
outcomes (eg, efficiency, equity, patient- centredness), 
often results in an inability to explain why an interven-
tion was (or was not) successful, hence limiting general-
isability.12–14 Undertaking an in- depth process evaluation 
alongside an intervention trial can provide a more detailed 
picture of contextual influences and complex causal 
processes, thereby helping policy- makers, clinicians and 
researchers interpret trial findings and understand how 
they might be applied elsewhere.14
The Hide and Seek Project (HaSP): Improving detec-
tion of patients with colorectal cancer (CRC) with a high 
risk of Lynch syndrome (LS)15 is a cluster RCT that will 
assess the effectiveness of two different implementation 
approaches aimed at improving detection of LS among 
patients with CRC, and is the focus of this in- depth 
process evaluation. LS is a hereditary cancer predisposi-
tion conferring an increased lifetime risk of colorectal, 
endometrial, ovarian and other cancer types.16 For LS 
carriers, risk management strategies (such as colonos-
copic surveillance, risk- reducing surgery) enable cancer 
prevention, early detection and improved survival.17–19 
These health benefits extend to the carriers’ relatives, 
who can undergo predictive genetic testing to clarify their 
cancer risks.
Failure to diagnose LS can result in otherwise prevent-
able cancer diagnoses and deaths, as carriers (and their 
at- risk relatives) remain unaware of their increased cancer 
risks and the need for heightened surveillance. While early 
methods of LS detection were largely reliant on reliant on 
family history assessment,20 21 tumour- based screening of 
LS- associated cancers by mismatch repair (MMR) protein 
immunohistochemistry (IHC) and/or microsatellite insta-
bility (MSI) analysis has offered a more sensitive means 
of identifying patients at high risk of LS.22 Those with 
abnormal tumour- screening results should be referred to 
a familial cancer clinic (FCC) for further investigations 
to establish an LS diagnosis (‘LS referral’). To increase 
detection of LS, evidence- based guidelines recommend 
universal tumour screening among all newly diagnosed 
patients with CRC.23 24 However, the condition remains 
largely underdiagnosed and current genetic referral 
practices are suboptimal. For example, an Australian 
study demonstrated that only 46% of patients with CRC 
at high risk of LS (based on tumour- screening results) 
were referred to an FCC for potential diagnostic testing.25 
Furthermore, Australia lacks a national policy for LS CRC 
tumour screening, and an estimated 53% of pathology 
laboratories are yet to adopt a universal approach.26 
Suboptimal LS tumour screening and referral rates have 
also been demonstrated internationally.27–29 While the 
problem of LS underdiagnosis is likely to be multifactorial 
(eg, failure to assess familial cancer risk in the primary care 
setting,30 suboptimal family communication and dissemi-
nation of LS risk information),31 these studies highlight a 
crucial need for hospital- based interventions targeting the 
LS tumour screening and referral pathway.
Despite clear preventative health benefits, adopting 
a systematic LS screening approach is challenging and 
requires organisational and behavioural change among 
multidisciplinary groups of health professionals involved 
in the recommended LS referral and diagnosis pathway.2 32 
Interventions aimed at improving uptake of evidence- 
based healthcare practices often have multiple compo-
nents (acting both independently and interdependently), 
and target change in multiple behaviour patterns at indi-
vidual, team and organisational levels.33 34 Owing to these 
complexities, numerous theoretical frameworks have 
been developed to guide the design and implementation 
of such interventions.4 However, the majority of inter-
ventions aimed at improving LS detection to date have 
focused on the uptake of various LS tumour screening 
strategies,25 35 with limited or no description of the imple-
mentation strategies or theoretical framework used (if 
any). While a US- based study is underway using a theory- 
driven implementation framework to enhance uptake 
of universal LS screening, such methods are yet to be 
applied in the Australian context.36
Furthermore, while theory- based approaches are 
recommended,4 37 38 there is little direct evidence as 
to whether they offer benefit over usual (non- theory 
informed) change processes. The Theoretical Domains 
Framework (TDF)39 synthesises a range of behavioural 
change theories to aid the identification of behaviour 
change determinants (eg, barriers or facilitators), which 
can then be specifically targeted by evidence- based 
intervention strategies which employ evidence- based 
behaviour change techniques (BCTs).40 41 The HaSP trial 
will compare the effectiveness of two identical imple-
mentation approaches, distinguished only by the use of 
theory—specifically the TDF4 and BCTs40—to identify 
barriers and design targeted interventions to improve 
diagnosis of LS across eight Australian hospital networks.
While it will be of interest and use to discover which 
works best—the theory or non- theory guided approach, 
simply testing this comparison will not be enough to facil-
itate our understanding about the factors affecting the 
success of either. Therefore, aligning with recommenda-
tions in the implementation science literature,6 42–44 there 
is a need to conduct a comprehensive, mixed- methods 
process evaluation alongside the HaSP trial to inves-
tigate how and why change has (or has not) occurred. 
Process evaluations are exploratory studies that seek to 
complement (but are distinct from) outcome evaluations 
by understanding the functioning of an intervention in 
practice.13 14 45 Recognising the value of process evalua-
tions in informing policy and practice, the UK Medical 
Research Council (MRC) produced guidance on theory 
and practice underpinning evaluations.14 This guidance 
highlights three aspects of implementation complexity 
that may impact intervention effectiveness: implementa-
tion, context and mechanisms of impact.
‘Implementation’, refers to ‘the structures, resources 
and processes through which delivery is achieved, and 
the quantity and quality of what is delivered’ (14:p.10). 
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When an intervention is unsuccessful, failure to assess 
these outcomes can result in an inability to distin-
guish between interventions that are inherently faulty 
in concept or design, and those that are poorly imple-
mented.11 ‘Context’, refers to the ways in which ‘external 
factors influence the delivery and functioning of inter-
ventions’ (14:p.10). ‘Mechanisms of impact’ refers to 
‘how intervention activities and participants’ (ie, in this 
case, individuals involved in an intervention who have 
completed process evaluation measures) interactions 
with them, trigger change’ (14:p.10). Intervention recip-
ients’ interactions with changes are shaped by context, 
and will occur differently in the presence of different 
barriers and facilitators, across intervention sites.43 
Capturing the way in which individuals interact with an 
intervention, and the influence of contexts, facilitates 
detailed identification of mechanisms of impact under-
lying behavioural change.14 Understanding the effects of 
these factors across different settings is thus key to inter-
preting trial outcomes, determining transferability and 
informing the design and implementation of subsequent 
interventions.33
Use of a theory- grounded approach for process evalu-
ation can further assess whether the intervention alters 
theoretical constructs proposed to mediate change, 
enabling testing of hypothesised causal pathways. A key 
gap in the process evaluation literature is the failure to 
incorporate theory, signifying missed opportunities to 
advance understanding about mechanisms of impact.46 
The HaSP trial presents a novel opportunity to address 
this gap by examining the impact of behaviour change 
theory (specifically the TDF) in intervention design and 
implementation, when compared with an approach that 
instead draws primarily on clinician intuition and tacit 
knowledge.
There is a further need to determine the resources 
associated with the implementation of health system 
interventions, and to evaluate their cost- effectiveness.12 
Without this, policy- makers lack the evidence needed to 
support funding and resource allocation for such efforts. 
Only a small proportion of implementation studies to 
date have incorporated cost data in their reporting, with 
the majority focusing only on intervention costs.12 47 48 
In addition to intervention costs, the cost of improving 
the implementation of interventions also depends on the 
implementation strategy used, and the service delivery 
setting.12 As such, the current process evaluation will 
incorporate measures to assess intervention and imple-
mentation costs, informing a separate cost- effectiveness 
study.
The current study will conduct a real- time process eval-
uation to gain an in- depth understanding of the factors 
influencing the effectiveness of the implementation 
approaches being tested in the HaSP trial. Specifically, we 
seek to achieve the following objectives:
1. Evaluate the implementation of the HaSP interven-
tion trial, via assessment of Proctor’s implementation 
outcomes.12
2. Examine contextual factors influencing the effective-
ness of the HaSP trial.
3. Identify potential mechanisms of impact to understand 
behavioural change and explain HaSP trial outcomes.
4. Document HaSP trial intervention and implementa-
tion costs, informing a separate cost- effectiveness study.
MEtHods And AnAlysIs
summary of the HasP trial
The HaSP trial commenced in June 2018 and is ongoing. 
A detailed protocol for the HaSP trial is available else-
where.15 Briefly, a cluster RCT will be used to test a theo-
retically driven structured implementation approach 
against a structured implementation approach (without 
the explicit use of theory) for improving LS referral prac-
tices for CRC patients in eight large Australian hospital 
networks. At each hospital network, a locally employed 
healthcare professional (eg, nurse, genetic counsellor) 
will be appointed and trained as an ‘Implementation 
Lead’ to coordinate the implementation approach, with 
ongoing support from researchers with expertise in 
implementation science and behavioural change.
At each hospital network, Implementation Leads will 
oversee seven HaSP study phases over an 18- month 
period. Figure 1 shows a breakdown of the key tasks 
in each phase, and how they relate to process evalua-
tion activities. A key distinction of the HaSP trial is the 
tailored approach used to develop targeted interven-
tion strategies to address site- specific referral barriers. 
To achieve this, the LS referral pathway will be mapped 
in detail (‘process- mapping’) alongside audit data 
at each site to identify potential gaps or bottlenecks, 
highlighting ‘target behaviours’ for change. These will 
vary between sites, and may affect different stages and 
departments involved in the LS referral pathway (eg, 
improvements in pathology systems and reporting, 
streamlined risk assessment processes for surgeons 
and/or oncologists).
The two trial arms differ only in the methods used 
to determine the key barriers to performing the target 
behaviour(s) and develop intervention strategies (phase 
4–5). In summary, the theory- driven implementation 
approach uses a questionnaire (Influences on Patient 
Safety Behaviours Questionnaire, IPSBQ) to identify 
site- specific barriers mapped to the domains of the TDF, 
allowing selection of corresponding BCTs in the design 
of targeted intervention strategies. In contrast, the ‘non- 
theory’ approach relies on the intuition and tacit knowl-
edge of hospital staff in the identification of barriers and 
design of intervention strategies (ie, without reference 
to the TDF or BCTs). Site- specific interventions are then 
implemented over a 6- month period. Behavioural change 
will be assessed in the HaSP tria via extraction of clinical 
data preimplementation and postimplementation (the 
primary intervention outcome being the proportion 
of patients with risk- appropriate completion of the LS 
tumour testing and referral pathway).
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Figure 1 Flow chart of the HaSP trial and process 
evaluation. BCTs, behaviour change techniques; HaSP, 
Hide and Seek Project; IPSBQ, Influences on Patient Safety 
Behaviours Questionnaire; LS, Lynch syndrome; MDT, 
multidisciplinary team; TDF, Theoretical Domains Framework.
Process evaluation design
Design framework and rationale
This process evaluation is an exploratory study that will 
be analysed and interpreted alongside the HaSP trial 
outcomes to explain how behaviour change occurs. The 
MRC guidance on process evaluations emphasises the 
importance of using both qualitative and quantitative 
data—analysed both separately and in combination—to 
enhance interpretation of intervention trial outcomes.14 
A mixed- methods study design was therefore developed 
to assess each of the process evaluation objectives, and will 
be undertaken in parallel to the HaSP trial for both inter-
vention (theory- driven implementation approach) and 
active control (‘non- theory’ implementation approach) 
arms at each of the eight Australian hospital networks.
Qualitative and quantitative data will be obtained 
from various sources throughout each phase of the 
HaSP trial to capture changes in implementation over 
time (see figure 1). Quantitative methods will be used 
to assess key HaSP process variables.14 Qualitative data 
will be used to capture in- depth stakeholder experiences 
of the intervention, generate hypotheses about causal 
pathways and to explain quantitative findings.14 Table 1 
provides a summary of measures and time points in rela-
tion to the four key process evaluation objectives, while 
table 2 provides additional detail about implementation 
outcome measures.
Process evaluation data will be used for summative 
purposes only, so as not to influence the HaSP trial 
outcomes.13 At trial completion, however, key process 
evaluation findings will be fed back to sites to enable 
potential intervention refinement. Given the minimal risk 
of harm from the HaSP trial process evaluation, a formal 
data monitoring committee will not be required. The 
process evaluation protocol has been reported according 
to the Standard Protocol Items: Recommendations for 
Interventional Trials checklist (see online supplementary 
additional file 1).49
Implementation outcomes
Implementation outcomes include: acceptability, adop-
tion, appropriateness, feasibility, fidelity, implementation 
cost, penetration and sustainability. To conceptualise 
and evaluate implementation, Proctor et al12 proposed a 
framework of eight ‘implementation outcomes’, which 
are conceptually distinct from service system and clin-
ical outcomes, and guidance on methods by which they 
can be measured. The Proctor framework12 will be used 
to capture implementation outcomes, which have been 
defined and operationalised in the context of the HaSP 
trial (see table 2). The HaSP trial can be divided into two 
key stages of implementation. The first stage involves 
the use of a step- by- step approach to identify barriers 
and develop targeted, site- specific intervention strategies 
(‘intervention development stage’, HaSP phases 1–5). 
In the second stage, intervention strategies are imple-
mented and evaluated over a 6- month period (‘interven-
tion implementation stage’; HaSP phases 6–7). Proctor’s 
implementation outcomes will be assessed throughout 
both of these stages (see table 2).
Theoretical orientation
Use of a theoretical framework for a process evalua-
tion offers the ability to test theoretical constructs and 
behavioural determinants proposed to mediate change.6 
Given that the TDF4 is the underlying theoretical frame-
work for the HaSP trial, it was also used to guide the 
design and analysis plan for the process evaluation. 
Explicit use of barrier- mapped change techniques40 41 for 
the development of intervention strategies in the theory- 
based HaSP trial arm will allow testing of prehypothesised 
causal pathways. In the non- theory trial arm, intuitively 
derived intervention strategies will be retrospectively 
coded to corresponding categories of BCTs.40 41 For each 
site, a detailed logic model will be developed to articu-
late assumptions about how the intervention will produce 
intended behaviour change effects.14 These will provide 
a visual representation of the interventions’ underlying 
theoretical constructs, contents, proposed causal path-
ways of behavioural change, and the conditions believed 
necessary for change to occur.13 50 These logic models 
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*Objective 1—Evaluate Proctor’s implementation outcome (see table 2); Objective 2—Examine contextual factors; Objective 3—Identify 
mechanisms of impact; Objective 4—Collect cost data to inform an economic evaluation.
†Timepoints throughout the HaSP trial: T0=preimplementation/baseline (Phase 1 of HaSP trial); T1=early implementation (6 months, phases 
2–5 of HaSP trial); T2=mid- implementation (12 months, phase 6 of HaSP trial); T3=end of implementation period (18 months, phase 7 of 
HaSP trial).
‡Used for qualitative analyses.
§Coding according to Proctor’s implementation outcomes applies to T3 (postimplementation) interviews only.
CFIR, Consolidated Framework for Implementation Research; HaSP, Hide and Seek Project; IL, implementation lead; IPSBQ, Influences on 
Patient Safety Behaviours Questionnaire; LS, Lynch syndrome; MANOVA, multivariate analysis of variance; MDT, multidisciplinary team; NA, 
not applicable; TDF, Theoretical Domains Framework.
will be developed in consultation with intervention devel-
opers (HaSP research team and Implementation Leads) 
and will be used to later explore and test potential mech-
anisms of impact.
While the TDF focuses on individual- level behavioural 
change, the Consolidated Framework for Implemen-
tation Research (CFIR)51 includes constructs designed 
to better capture organisational- level determinants 
of change.52 The CFIR is a taxonomy of 31 constructs 
(across five major domains) from multiple disciplines 
(eg, psychology, sociology, organisational change) that 
are believed to influence the implementation of complex 
interventions.51 53 The CFIR has been widely used in 
implementation studies, and has sample interview guides 
available online ( www. cfirguide. org) from which relevant 
constructs can be selected by researchers.51 Together with 
the TDF, the CFIR will be used in the qualitative analysis 
to develop a broader understanding of the underlying 
implementation context.
recruitment
Prior to commencing the process evaluation, eight hospital 
networks and Implementation Leads have been recruited 
via the HaSP trial. Given that Implementation Leads have 
been employed from within each hospital network, they 
will have existing contacts and the ability to identify key 
staff from various departments involved in the LS iden-
tification and referral pathway (eg, colorectal surgeons, 
oncologists, pathologists, genetic counsellors, adminis-
trators; referred to hereafter as ‘LS stakeholders’). Using 
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Table 2 Assessing Proctor’s implementation outcomes in the HaSP trial
Implementation 
outcome*




Acceptability Do LS stakeholders perceive the HaSP 
implementation approaches and intervention 
strategies to be agreeable, palatable or satisfactory?





    Post- training semistructured 




Adoption Are LS stakeholders willing to adopt the HaSP 
implementation approaches and intervention 
strategies?













Appropriateness Do LS stakeholders believe the HaSP 
implementation approaches to be relevant/ 
compatible for their hospital setting, their provider 
role and their patients?
Post- training semistructured 













Feasibility Can the HaSP implementation approaches and 
intervention strategies be successfully carried out 
within each of the hospital settings?
Post- training semistructured 














Fidelity To what extent were the HaSP implementation 
approaches and intervention strategies carried out 
as intended (according to trial arm) at each hospital 
network?














    Fidelity checklist56 65 Intervention 
implementation




What was the absolute cost of carrying out 
the HaSP implementation approach (including 
implementation of intervention strategies) at each 
hospital network? What was the additional cost of 
using a theory- grounded implementation approach?
















Penetration To what degree was the HaSP implementation 
approach and intervention strategies integrated 
within each hospital networks?







    Fidelity checklist12 Intervention 
implementation
Sustainability To what extent were the intervention strategies 
developed via the HaSP implementation approach 
maintained within each hospital network?




    Fidelity checklist12 Intervention 
implementation
*See Proctor et al for implementation outcome definitions12
†All interviews and meeting/focus group observations will be conducted by a member of the research team, fidelity checklists will be 
completed by a member of the Implementation Team and project logs will be completed by the Implementation Leads.
HaSP, Hide and Seek Project; LS, Lynch syndrome; MDT, multidisciplinary team.
Table 2 Continued
snowball methods, LS stakeholders will be invited by the 
Implementation Lead to participate in process evaluation 
activities at various time points (figure 1).
data sources
Video analysis of IL training
Training of the Implementation Leads will be video 
recorded for analysis. The purpose of the recording will 
be to assess the fidelity of the training delivery, and ensure 
there is no contamination in the training components 
delivered between the two implementation approaches.
Implementation lead post-training interviews
Following completion of a 1- day training package, each 
Implementation Lead will be invited to participate in a 
semistructured interview (online supplementary appendix 
1) to understand their experiences of the training and antic-
ipated challenges at their site. Interviews will be conducted 
individually by telephone by an independent member of 
the research team (ie, not involved in training delivery) 
and will be audio recorded and transcribed for thematic 
analysis. These will be used to assess the implementation 
outcomes of acceptability, appropriateness and feasibility, 
as per the Proctor framework.12
Influences on Patient Safety Behaviours Questionnaire
The IPSBQ is a questionnaire designed to measure psycho-
social and environmental barriers (eg, knowledge, envi-
ronment/resources, memory and emotion) to performing 
clinical practice target behaviour(s), and is theoretically 
underpinned by the TDF domains.4 54 The IPSBQ has been 
used in the context of nasogastric tube misplacement54 
adapted for use in other contexts,55 and has demonstrated 
internal consistency, construct validity and discriminant 
validity.54 The IPSBQ has 34- items (each mapped to a TDF 
domain), takes less than 5 min to complete, and has a modi-
fiable end statement allowing application across a range 
of settings and target behaviours.54 This is particularly 
useful in the context of the HaSP trial, given that the LS 
referral pathway involves multiple behaviours and decision 
points (eg, performing MMR IHC, initiating discussion 
about referral with at- risk patients, writing a referral letter) 
among individuals from various hospital departments (eg, 
pathology, surgery, oncology, genetics). Furthermore, the 
tool has been used successfully to identify barriers in the 
context of LS in the HaSP pilot study.32 The IPSBQ will be 
distributed by Implementation Leads to LS stakeholders 
at each hospital network at time points before and after 
the intervention implementation to assess for changes in 
perceived LS referral barriers. Implementation Leads will 
be encouraged to seek a large sample (approximately 
20–40, depending on hospital network size) with represen-
tation from each of the key departments involved in the 
LS referral pathway to ensure correct identification of key 
barriers.
Interviews with health professionals involved in the LS referral 
pathway
Implementation Leads will invite LS stakeholders to partic-
ipate individually in semi- structured telephone interviews 
preimplementation and postimplementation, aiming for 
8–10 participants per site. These will explore current LS 
referral practices, perceptions about LS referral barriers 
and experiences of the implementation process (postim-
plementation). Interview questions (see online supplemen-
tary appendix 2) were developed to reflect TDF domains 
and relevant CFIR constructs (eg, culture, tension for 
change, readiness for implementation). TDF- based ques-
tions were adapted from, and expanded on, the interview 
guide developed by Gould et al,42 while CFIR- based ques-
tions were selected from the sample interview guide devel-
oped by Damschroder et al (available online: www. cfirguide. 
org). Interviews will be audio- recorded and transcribed for 
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thematic analyses. They will also be used to assess the imple-
mentation outcomes of acceptability, adoption, appropri-
ateness and feasibility.
Audio analysis of meetings/focus groups
Implementation leads will be responsible for audio- 
recording meetings and focus groups held throughout 
the HaSP trial, which will be structured according to the 
schedules prescribed in the trial protocol (see figure 1 
for summary).15 These audio recordings will serve dual 
purposes for the HaSP trial and process evaluation, and 
will therefore be analysed separately according to these 
purposes. For the purpose of the HaSP trial, meetings and 
focus groups will be analysed by the Cancer Council New 
South Wales research team to guide the appropriate selec-
tion of target behaviours for change, barriers to behavioural 
change and targeted intervention strategies (see HaSP 
trial protocol for further detail).15 For the purpose of this 
process evaluation, the audio recordings will be used to 
gain a more in- depth understanding of barriers, the impact 
of the change techniques designed into the interventions, 
and to generate hypotheses about potential mechanisms 
of impact, as guided by the analysis approach described 
under ‘Data Analysis’. Audio recordings of meetings and 
focus groups will also be used to assess the implementation 
outcomes of adoption, appropriateness and fidelity. Imple-
mentation Leads will each aim to recruit 8–10 LS stake-
holders from various departments to participate in each 
meeting and focus group.
Multidisciplinary team meeting observation
Where relevant and possible, a researcher will attend and 
observe CRC multidisciplinary team (MDT) meetings. 
The researcher will complete semistructured observation 
checklists (online supplementary appendix 3) for each 
CRC patient presented. Checklist items were adapted 
from the observation materials developed for the ‘Audit 
and Feedback INterventions to Increase evidence- based 
Transfusion practIcE’ (AFFINITIE) Programme,42 a 
UK- based intervention study aimed at improving evidence- 
based blood transfusion practices. The checklist will assess 
whether the following information was reported for each 
case presentation: personal history of polyps and/or other 
cancers, cancer family history, MMR and/or MSI status, 
LS risk and indication for FCC referral. Field notes will 
also be collected, documenting observed MDT processes 
(eg, use of proforma), group dynamics, decision- making 
behaviours, staff roles and interactions. These will be used 
to assess changes in LS referral processes preintervention 
and postintervention, identify cultural changes, investi-
gate mechanisms of impact and assess the implementation 
outcome fidelity (for sites where MDTs are the focus of 
intervention strategies).
Fidelity checklists
Based on intervention packages developed at each 
site in phase 5 of the HaSP trial, intervention- specific 
‘fidelity checklists’ will be developed in consultation with 
Implementation Leads to assess whether key intervention 
components have been delivered as planned. Fidelity check-
lists will differ between sites, as intervention strategies will 
be tailored to address context- specific barriers. Checklist 
development will be guided by the steps outlined by Stein 
et al,56 while Proctor’s ‘Prerequisites to measuring imple-
mentation strategies’57 will be used to further refine scale 
items to ensure measurability. Checklists will be completed 
by two members of the Implementation Team (enabling 
assessment of inter- rater reliability) every 3 weeks during 
the 6- month intervention implementation period (phase 6 
of HaSP trial). Dichotomous scaling will be used to increase 
inter- rater reliability,56 58 however free- text space will enable 
documentation of any variations made to the intended 
intervention strategies. Fidelity checklists will be used to 
assess the implementation outcome of fidelity, penetration 
and sustainability.
Implementation lead project log
For each HaSP phase, Implementation Leads will complete 
a ‘Project Log’, using a template provided by the research 
team (online supplementary appendix 4). The Project Log 
will document the implementation tasks carried out, time 
taken, resources used to complete each given task, staff 
attendance at meetings and focus- groups, and any chal-
lenges encountered. Project Log data will be used to assess 
the implementation outcomes of fidelity, feasibility, adop-
tion, implementation cost, penetration and sustainability, 
and will also inform a separate cost analysis.
Patient and public involvement
While the HaSP trial targets the behaviours of health-
care professionals (as determined by audit and process 
mapping activities) to improve LS detection, ongoing 
consumer input from a single cancer patient was sought for 
the overall study design, conduct, reporting and dissemi-
nation of the research. The consumer was sought via the 
Cancer Voices NSW ‘Consumer Involvement in Research 
Programme’. The programme trains consumers in the 
basics of cancer research, and matches them with an appro-
priate researcher. The consumer is provided with regular 
telephone or email study updates, through which opportu-
nities for input are raised and discussed. Future study find-
ings may also be presented at LS patient and other relevant 
consumer forums.
data analysis
The process evaluation will be analysed using a mixed- 
methods approach.14 Table 1 summarises the analysis 
approaches in relation to study measures and objectives. 
To investigate context and mechanisms of impact, results 
from the IPSBQ will be analysed using descriptive statistics 
and multivariate analysis of variance to assess for differences 
in perceived barriers preintervention and postintervention 
implementation. Where possible, mediation analysis will be 
performed to assess the degree to which changes in specific 
barriers influence changes in behaviour (ie, mechanisms of 
impact).
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De- identified interview, meeting and focus group tran-
scripts will undergo qualitative analysis in three stages, 
guided by the approach used by Gould et al.42 The first stage 
will involve a mixed deductive and inductive thematic anal-
ysis,59 with coding of transcripts guided by TDF domains4 
and CFIR constructs,51 while allowing generation of new 
themes outside these frameworks. Coding of postimple-
mentation interviews will also be guided by Proctor’s imple-
mentation outcomes.12 The second stage will involve an 
inductive analysis approach, by which similar responses 
within domains and/or constructs will be grouped and 
theme labels generated. In the third stage, key themes, 
domains and constructs will be identified based on 
frequency (eg, elicited in >60% participants) and expressed 
importance.42 The first transcript will be coded simultane-
ously by two researchers (familiar with the TDF and CFIR) 
to devise a strategy for subsequent transcripts. Subsequent 
transcripts will be coded by a single reviewer, with 10% 
independently double coded by a second reviewer to deter-
mine level of agreement.60 Reviewers will meet to resolve 
disagreements, and the advice of a third reviewer will be 
sought where consensus cannot be reached. Analysis will 
be performed iteratively, so that themes emerging in early 
pre- implementation interviews can be further explored in 
postimplementation interviews.14
The same qualitative analysis approach will be used for 
both theory and non- theory trial arms. Although partici-
pants in the non- theory group will not be exposed to the 
TDF, analysis with reference to the TDF (and CFIR) will 
enable assessment of whether intuitively identified barriers 
and intervention strategies align with a theoretical frame-
work of behaviour change, and inferences about potential 
mechanisms of impact. Results of these exploratory anal-
yses will be assessed in conjunction with the HaSP trial 
outcome measures (changes in the proportion of patients 
with risk- appropriate completion of the LS referral pathway, 
proportion of patients who were referred to genetic 
services, proportion of referred patients who attended 
genetic services, and proportion of patients with missing 
testing and referral data) to determine which mechanisms 
of impact are associated with behavioural change. Qualita-
tive data will also be used to further explain any differences 
observed between trial arm sites.
Fidelity checklists, Implementation Lead project logs 
and MDT observation forms will be analysed using both 
quantitative and qualitative approaches (descriptive statis-
tics and coding according to relevant frameworks; see 
table 1). These data will be triangulated with quantitative 
data on barriers and practice change. Descriptive statis-
tical analysis of time and resource data (drawn from the 
Implementation Lead ‘Project Log’) will be conducted, 
including reporting of costs by stage and funder. These 
costs will be used to inform a future cost- effectiveness 
study.
dIsCussIon
Use of a theory- based, mixed- methods process evalua-
tion alongside a complex intervention trial is the optimal 
approach to understanding behavioural change, and is 
novel in the hereditary cancer setting. Furthermore, the 
HaSP trial is the first to compare a theoretically driven 
implementation approach against a non- theoretically 
driven approach, while keeping all other elements of 
structured implementation constant. Conducting an 
in- depth process evaluation of the HaSP trial presents a 
unique opportunity to advance understanding and refine 
the role of theory in implementation.
Results from this study will be used to interpret HaSP 
trial outcomes, and optimise the design of future inter-
ventions to increase detection of patients with LS on a 
larger scale and across different contexts. Identifying 
more patients with LS can save lives by enabling access to 
risk management strategies aimed at cancer prevention 
and early detection. Such work can be applied to improve 
detection of other genetic conditions, and is particularly 
timely in the hereditary cancer setting as health systems 
struggle to integrate findings from the rapidly evolving 
field of genomic research into routine clinical practice.3 32
Beyond LS, findings from this study will contribute to 
implementation and behavioural science efforts more 
broadly by advancing understanding of (1) factors 
affecting the success of implementation strategies to 
enhance uptake of evidence- based research and (2) the 
role and importance of theory in intervention design. 
Findings from this process evaluation will help to under-
stand what works, in what contexts, why and at what 
costs—hence optimising the design of future implemen-
tation strategies to promote uptake of evidence- based 
best practice guidelines within health systems, thereby 
improving patient care and outcomes.
Ethics and dissemination
Ethical approval has been granted for this study by the 
Royal Prince Alfred Hospital Human Research Ethics 
Committee (ref HREC/17/RPAH/542). Site- specific 
governance will be obtained for each site prior to 
commencing study activities, and individual consent 
will be obtained prior to participation in study activi-
ties. Amendments to the original submitted protocol are 
subject to further ethical review, and will be communi-
cated to investigators and participants (where relevant) 
on approval. Results will be disseminated via publications 
in peer- reviewed journals and presentations at relevant 
conferences.
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